Korro Bio, Inc. (KRRO)
NASDAQ: KRRO · Real-Time Price · USD
15.94
-1.51 (-8.63%)
Mar 31, 2025, 10:44 AM EDT - Market open
Korro Bio Revenue
In the year 2024, Korro Bio had annual revenue of $2.27M. Korro Bio had revenue of $2.27M in the quarter ending December 31, 2024.
Revenue (ttm)
$2.27M
Revenue Growth
n/a
P/S Ratio
68.50
Revenue / Employee
$21,837
Employees
104
Market Cap
149.61M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.27M | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKRRO News
- 13 days ago - Korro Reports Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 17 days ago - KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency - GlobeNewsWire
- 4 weeks ago - Korro to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 4 months ago - Korro to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency - GlobeNewsWire
- 4 months ago - Korro to Present at the Jefferies London Healthcare Conference - GlobeNewsWire
- 5 months ago - Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board - GlobeNewsWire
- 6 months ago - Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society - GlobeNewsWire